Published in Proc Natl Acad Sci U S A on December 01, 1988
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A (2001) 1.61
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest (2006) 1.43
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A (1999) 1.16
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A (1992) 1.11
Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc Natl Acad Sci U S A (2004) 1.08
A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc Natl Acad Sci U S A (1997) 0.99
Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci U S A (1991) 0.98
Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci U S A (2004) 0.95
Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc Natl Acad Sci U S A (1993) 0.94
Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology (2001) 0.90
New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol (1996) 0.83
What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol (2004) 0.83
Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Proc Natl Acad Sci U S A (1999) 0.82
Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci U S A (1998) 0.81
A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci U S A (1996) 0.80
BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease. PLoS One (2011) 0.79
Active suppression induced by repetitive self-epitopes protects against EAE development. PLoS One (2013) 0.78
Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther (2013) 0.75
T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol (1985) 6.98
Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine. Biochem J (1962) 4.82
T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature (1987) 3.96
Immunological self, nonself discrimination. Science (1987) 2.59
Interaction of peptide antigens and class II major histocompatibility complex antigens. Nature (1987) 2.34
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med (1987) 2.21
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci U S A (1988) 1.51
Regulation of autoimmune disease physiological and therapeutic. Immunol Rev (1986) 1.41
Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol (1979) 1.40
Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex. FEBS Lett (1970) 1.27
Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol (1974) 1.24
In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol (1973) 1.17
Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol (1973) 1.17
Current perspectives of neuroimmunologic disease: multiple sclerosis and experimental allergic encephalomyelitis (1,2). Clin Immunol Rev (1983) 1.16
Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice. J Immunol (1983) 1.13
Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry (1976) 1.05
Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice. Nature (1980) 0.97
Human cellular immune response to copolymer I and myelin basic protein. Neurology (1986) 0.85
Nature and function of antigen-specific T-cell lines and their products. Physiol Rev (1986) 0.80
Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med (1965) 7.27
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
The localization of antigen in relation to specific antibody-producing cells. I. Use of a synthetic polypeptide [(T,G)-A--L] labelled with iodine-125. Immunology (1966) 3.09
Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. J Exp Med (1967) 2.41
Antigenicity of some new synthetic polypeptides and polypeptidyl gelatins. Biochem J (1964) 2.40
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci U S A (1966) 2.25
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline. J Biol Chem (1968) 2.19
Immunological studies with synthetic polypeptides. Adv Immunol (1966) 2.10
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
Modified stock-eye ocular prosthesis. J Prosthet Dent (1985) 2.03
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Antigenicity: some molecular aspects. Science (1969) 1.98
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
Anti-influenza response achieved by immunization with a synthetic conjugate. Proc Natl Acad Sci U S A (1982) 1.85
Chemical characterization and subunit structure of human N-acetylhexosaminidases A and B. Biochemistry (1976) 1.84
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
The nature of the antigenic determinant in a genetic control of the antibody response. J Exp Med (1969) 1.74
Regulation of antibody response by cells expressing histamine receptors. J Exp Med (1972) 1.70
Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci U S A (1971) 1.67
Antigen design and immune response. Harvey Lect (1973) 1.67
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J (1997) 1.58
The genetic control of antibody specificity. J Exp Med (1969) 1.58
Comparative genetics of nucleotide binding site-leucine rich repeat resistance gene homologues in the genomes of two dicotyledons: tomato and arabidopsis. Genetics (2000) 1.56
Thymus-independence of slowly metabolized immunogens. Proc Natl Acad Sci U S A (1972) 1.52
Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A (2000) 1.52
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst (1988) 1.49
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene (1996) 1.48
Changing indications for enucleations in Hadassah University Hospital, 1960-1989. Ophthalmic Epidemiol (1995) 1.48
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A (1979) 1.48
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res (1975) 1.48
Synthetic antigens composed exclusively of L- or D-amino acids. I. Effect of optical configuration on the immunogenicity of synthetic polypeptides in mice. Immunology (1967) 1.47
Receptors for histamine can be detected on the surface of selected leukocytes. Science (1972) 1.46
Preparation and characterization of poly-DL-alanyl rabbit gamma-globulin. J Biol Chem (1965) 1.44
Chemically defined antiviral vaccines. Annu Rev Microbiol (1980) 1.41
Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol (1979) 1.40
Acute upper gastrointestinal bleeding in Jerusalem 1988-91: causes, characteristics and relation to nonsteroidal anti-inflammatory drugs. Isr J Med Sci (1993) 1.40
Specific leukocyte receptors for small endogenous hormones. Detection by cell binding to insolubilized hormone preparations. J Clin Invest (1973) 1.39
Seasonal fluctuations in acute upper gastrointestinal bleeding: lack of effect of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol (1992) 1.39
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol (1998) 1.38
Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. Proc Natl Acad Sci U S A (1976) 1.37
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Anti-penicilloyl antibodies: detection with penicilloylated bacteriophage and isolation with a specific immunoadsorbent. Nature (1967) 1.34
Antibodies elicited with conjugates of nucleosides with synthetic polypeptides. Biochim Biophys Acta (1967) 1.34
Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate. Proc Natl Acad Sci U S A (1969) 1.32
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A (1995) 1.32
Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin. Proc Natl Acad Sci U S A (1984) 1.32
Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci (1984) 1.30
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol (1996) 1.30
Determinants of antigenic molecules responsible for genetically controlled regulation of immune responses. Proc Natl Acad Sci U S A (1976) 1.30
Soluble antigen-antibody complexes as intermediates in the purification of antibodies in 8 molar urea. Arch Biochem Biophys (1966) 1.30
Antibodies to papain. A selective fractionation according to inhibitory capacity. Biochemistry (1967) 1.30
The localization of antigen in lymph nodes and its relation to specific antibody-producing cells. II. Comparison of iodine-125 and tritium labels. Immunology (1967) 1.29
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun (1993) 1.29
Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex. FEBS Lett (1970) 1.27
Antibodies against synthetic peptides of the B subunit of cholera toxin: crossreaction and neutralization of the toxin. Proc Natl Acad Sci U S A (1983) 1.26
Recovery of antibody activity upon reoxidation of completely reduced polyalanyl heavy chain and its Fd fragment derived from anti-2,4-dinitrophenyl antibody. Biochemistry (1968) 1.26
Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A (1982) 1.26
Differences in immune response to synthetic antigens in two inbred strains of guinea-pigs. Immunology (1967) 1.26
catELISA: a facile general route to catalytic antibodies. Proc Natl Acad Sci U S A (1993) 1.26
T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol (1993) 1.25
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res (1992) 1.24
The role of thymus cells in the immune response to poly(Tyr, Glu)-polyD L Ala--polyLys as a function of the genetic constitution of the mouse strain. Eur J Immunol (1974) 1.24
Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol (1974) 1.24
Synthetic vaccines. J Immunol Methods (1983) 1.23
Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity. Infect Immun (1988) 1.23
In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol (1973) 1.17
Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol (1973) 1.17
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A (1999) 1.16
Thymus independence of a collagen-like synthetic polypeptide and of collagen, and the need for thymus and bone marrow-cell cooperation in the immune response to gelatin. J Exp Med (1974) 1.15
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol (1996) 1.15
The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Cancer Res (1975) 1.15